Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose cytarabine with or without tosedostat in older adults with AML or high-risk MDS
ACTRN12612000848808Phase 3Terminated
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Aug 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) comparing Low-dose cytarabine with Low-dose cytarabine + tosedostat (2 arms). Primary endpoint: Complete remission. Started Aug 2016; status: terminated.
02
Drugs
tosedostatcytarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ACTRN12612000848808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000848808.